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Abstract
Autoantibodies present in the serum of patients with a variety of inflammatory diseases have
proven useful as diagnostic markers and as probes with which to elucidate biochemical and
signaling pathways. The mechanisms governing the generation of autoantibodies remain
elusive, constituting a critical missing link in our understanding of rheumatologic illnesses.
Several lines of experimentation in recent years have strongly implicated events surrounding
cell death in this process. This review will address the potential role played by death-specific
modifications of autoantigens in bypassing tolerance to highly conserved autoantigens,
including nucleic acids, lipids, and proteins.
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Introduction
A hallmark of autoimmune diseases such as systemic
lupus erythematosus (SLE), scleroderma, rheumatoid
arthritis, type I (insulin-dependent) diabetes mellitus, and
dermatomyositis is the production of highly specific
autoantibodies that recognize evolutionarily conserved
molecules. The mechanisms by which these largely intra-
cellular molecules are recognized as foreign are poorly
understood. Many recent studies have implicated an
important role for cell death processes in mediating the
bypass of tolerance to these autoantigens. Since this
subject was last reviewed, a number of new autoantigen
modifications that accompany apoptotic and nonapoptotic
cell death have been described [1,2]. This review serves
as an update on this expanding field, and defines new
areas of research that should be explored in order to
resolve this important scientific conundrum.
Brief history of apoptosis and autoantibodies
Apoptosis and its role in the development of autoimmunity
have been extensively reviewed by several authors [1–8],
and the reader is referred to that work for a more compre-
hensive review of the topic. Apoptosis is a morphologically
and biochemically defined form of cell death that plays a
significant role in the deletion of autoreactive lymphocytes,
removal of cells infected with virus, elimination of cancer-
ous cells, and embryogenesis of complex multicellular
organisms. As one might expect, defects in cell death
have been implicated in the development of autoimmune
diseases, persistent viral infection, malignancy, and devel-
opmental defects.
That apoptosis might play an important role in bypassing
tolerance to intracellular autoantigens was first demon-
strated by LeFeber et al in 1984 [9••]. Those investigatorsArthritis Research    Vol 2 No 2 Utz et al
observed that nuclear antigens that are present in cultured
human keratinocytes derived from neonatal foreskin relo-
calized after exposure to ultraviolet irradiation. Several
antigens including Ro, small nuclear ribonuclear protein
(snRNP), and Smith complex relocalized from their normal
nuclear address to the cell surface membrane. This work
was confirmed and extended by Golan et al in 1992 [10•]
when they demonstrated that keratinocytes derived from
the skin of SLE patients avidly bound autoantibodies at
their cell surface membrane following ultraviolet A and
ultraviolet B exposure. This occurred in a less dramatic
manner when the keratinocytes were derived from healthy
control patients. These experiments suggested that ker-
atinocytes from SLE patients were significantly more sen-
sitive to ultraviolet light, which is an important cause of
SLE dermatologic manifestations. This correlated with the
observed relocalization of autoantigens to a locale where
they might be readily accessible to components of the
immune system, including lymphocytes and antigen-pre-
senting cells (APCs).
The morphologic features of apoptotic cell death had
been described over a decade before these important
reports [11••]. However, it was not until the now seminal
experiments performed by Casciola-Rosen et al [12••]
were completed that an important discovery was made –
that ultraviolet-irradiated keratinocytes were in fact under-
going apoptosis. The autoantigens were shown to cluster
in two discrete cell surface ‘membrane blebs’. The larger
blebs (called apoptotic bodies) contained predominantly
Ro, La, snRNPs, and nucleosomal DNA. The smaller struc-
tures were recognized by autoantibodies specific for
endoplasmic reticulum components, as well as Ro and
ribosomal components [12••]. The same group of investi-
gators also showed that the cell is further modified by the
increased external cell surface expression of phos-
phatidylserine, a procoagulant that has been implicated in
the antiphospholipid antibody syndrome [13].
Interestingly, several other apoptotic stimuli lead to
autoantigen relocalization, including infection of cells with
Sindbis virus [14]. Sindbis viral particles colocalize with
ribosomal and endoplasmic reticulum components exclu-
sively in small blebs, generating packages of autoantigens
that are closely associated with viral proteins. Other mole-
cules have been observed in association with keratinocyte
surface blebs, including complement C1q (complete defi-
ciency of which is almost uniformly associated with SLE)
[15]. The clustering of autoantibodies on the surface of
apoptotic cells has also been described for antineutrophil
cytoplasmic autoantibodies, a specific marker for Wegen-
er’s granulomatosus. Granules of apoptotic, but not
untreated neutrophils bind antineutrophil cytoplasmic
autoantibodies in a region immediately beneath the intact
cell membrane [16]. These studies demonstrate a second
important piece to the autoantibody puzzle – not only are
the autoantigens in locations where they ordinarily are not
present, but they are differentially packaged in a manner that
may partly explain the diversity and combination of autoanti-
body profiles that characterize SLE and subsets of SLE.
In addition to their intracellular relocalization in response
to stressful stimuli, many autoantigens are specifically
modified by enzymes that are activated as part of the cell
death program. For example, at least 38 autoantigens are
substrates for nearly a dozen mammalian and viral pro-
teases (Table 1). Some antigens are nonproteolytically
modified (eg by kinases and phosphatases), whereas
other autoantigens are directly modified by toxins such as
mercury, presumably by processes that are enzyme-inde-
pendent (Table 2). This extensive list of autoantigen modi-
fications, and the specific roles that they may play in
generating molecules that are recognized as foreign by
the immune system, are the focus of the remainder of the
present review.
Modifications of autoantigens in association
with apoptotic cell death
Modifications of chromatin components
A biochemical hallmark of apoptotic cell death is the
cleavage of DNA into oligosome-sized fragments, called
‘DNA ladders’ when analyzed by ultraviolet illumination of
ethidium-stained agarose gels. The molecular details of
this process have now been elucidated and are reviewed
in detail elsewhere [17•]. Chromatin modified in this way
is present in apoptotic blebs, together with protein
autoantigens [12••]. Anti-DNA antibodies are intimately
associated with SLE, and their presence has both diag-
nostic and prognostic significance (reviewed in [18•]).
Before the general acceptance of DNA ‘laddering’ as an
important characteristic of apoptosis, it was observed
that serum derived from human SLE patients contained
DNA that had been similarly processed, whereas ‘DNA
ladders’ were absent from healthy control sera [19].
Analysis of serum from young MRL/lpr/lpr mice [20] has
yielded similar results.
If sera from SLE patients contains circulating apoptotic
debris, from where does it arise? Cells derived from SLE
patients have been reported to undergo apoptosis sponta-
neously at a faster rate, and some apoptotic cells, includ-
ing peripheral blood neutrophils and lymphocytes,
circulate at higher levels in the blood of SLE patients
[21,22]. This phenomenon appears to be a unique charac-
teristic of cells from SLE patients, because most other dis-
eases associated with an excess of apoptotic cells (eg
acquired immune deficiency syndrome and systemic vas-
culitis) are generally not associated with high titers of spe-
cific autoantibodies [23]. Circulating nucleosomes can be
detected in the blood of patients undergoing radiation
therapy or chemotherapy, however [24]. Although unique
autoantibodies have been described in association withhttp://arthritis-research.com/content/2/2/101
specific malignancies, none are known to recognize pro-
teins that are modified during cell death [25–28].
In addition to cleavage of internucleosomal DNA, the
question also arises regarding whether chromatin and
associated proteins might be modified in other ways. A
recent report [29] suggested that ‘apoptotic nucleo-
somes’ isolated from cell supernatants of apoptotic
hybridoma cells contain degraded histone H3 and H4.
Another report [30] suggested that DNA methylation and
deoxycytosine/deoxyguanine content of nucleosomes pre-
pared from apoptotic lymphocytes is also abnormal. To
date no other specific modifications of nucleosomes have
been reported to occur as a result of apoptosis. Taken
together, these studies suggest that chromatin that is
modified during apoptosis may circulate, either in native
form or packaged in apoptotic bodies, in the serum of
patients with a variety of systemic autoimmune diseases.
Clearly other factors are required for the apoptotic mater-
ial to serve as an immunogen in SLE patients and auto-
immune mice.
Nucleolytic degradation of RNA
To date, four RNA molecules have been identified as sub-
strates for ribonuclease(s) that are activated during apop-
tosis (for review [17•]). These include the 18S and 28S
ribosomal RNAs, the Ro-associated Y RNAs, and the
U1-snRNA molecule. Each of these RNA molecules is
associated with particles that are common targets of the
immune response in SLE and mixed connective tissue
disease (MCTD) [18•]. The details of these discoveries
have been extensively covered in an excellent recent
review [17•] and will be touched on only briefly here.
The 18S ribosomal RNA was shown to undergo unique
cleavage in response to DNA-damaging stimuli such as
g-irradiation [31,32]. Other than the 72-kDa subunit of the
signal recognition particle and the L10E ribosomal protein,
both of which are cleaved during apoptosis, the 18S and
28S ribosomal RNA molecules are the only other con-
stituents of the ribosome that are known to undergo an
apoptosis-specific modification [33,34]. The Y RNA mole-
cules, small RNAs that exist in complex with the Ro
autoantigen in the cytoplasm, are degraded in response to
a number of stressful stimuli [35]. Cleavage is caspase-
dependent and is inhibited by zinc, small peptide caspase
inhibitors, and bcl-2. Ro remains bound to the degradation
products, protecting a highly conserved region of the Y
RNA. The final RNA moiety that is known to be cleaved, the
U1-snRNA molecule, also remains associated with protein
constituents of the U1-snRNP [36]. These constituents,
which include Smith complex proteins found in several
snRNPs, as well as U1-snRNP-specific proteins such as
U1-70 kD and U1A, are major targets of the immune
response in SLE and MCTD, respectively. What role cleav-
age of these RNA moieties plays in the development of an
immune response to components of these particles is cur-
rently unknown, but antibodies capable of directly recogniz-
ing individual RNAs have been described (for review [17•]).
The nuclease(s) responsible for these cleavage events
presently remain unidentified, as are the effects that RNA
cleavage may have on cell death pathways.
Caspase-mediated protein cleavage
The major ‘executioners’ of cell death are ‘caspases’, a
family of cysteine proteases that cleave substrate proteins
immediately after aspartic acid residues (for review [37•]).
At least 14 members of this protease family have been
described. Some of the earliest caspase substrates to be
identified were already known to be autoantigens, sug-
gesting to these pioneering investigators that cleavage of
autoantigens during cell death might contribute to their
immunogenicity [12••,38]. Four major screening assays
have been reported that attempted to identify autoanti-
gens that are cleaved during apoptosis. Three of these
used human autoimmune sera as probes to identify
cleaved proteins by Western blotting [12••,39,40]. The
fourth study [41] employed sera to immunoprecipitate
autoantigen particles from lysates prepared from radio-
labeled apoptotic cells. A number of other autoantigens
have been identified as caspase cleavage substrates by
other investigators studying other systems. The results of
these screens have been summarized in several recent
reviews and are compiled in Table 1 [1].
Autoantigen phosphorylation
Many proteins are recognized by autoantibodies but are
not substrates for apoptotic proteases such as caspases
and granzymes (see Autoantigen cleavage by cytotoxic
T lymphocyte granule proteases below). In an attempt to
identify other post-translational modifications of autoanti-
gens that might render them immunogenic, we screened a
large number of human and mouse autoimmune sera for
the ability to precipitate novel phosphoproteins from radio-
labeled apoptotic Jurkat cell lysates [41,42]. Almost all
lupus sera are capable of precipitating new phosphopro-
teins in such an assay, suggesting that this autoantigen
modification might also be of importance [41]. Of the
eight phosphoproteins initially discovered in this way, we
have definitively identified four of the proteins as members
of the serine arginine family of RNA splicing factors
[41,42]. Serine arginine proteins are critical regulators of
constitutive and alternative messenger RNA splicing (for
review [43•]). Their splicing activity is regulated by
reversible serine phosphorylation of their carboxyl-terminal
serine arginine motifs by a number of interesting kinases,
including the serine arginine protein kinases SRPK1 and
SRPK2, and the scleroderma autoantigen topoisomerase I
[44–48]. The SRPK activity of topoisomerase I has only
recently been discovered and characterized [48]. Intrigu-
ingly, SRPK1 and topoisomerase I are cleaved by cas-
pases during apoptosis, suggesting that their proteolysisA
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Table 1
Proteolytic cleavage of autoantigens during apoptosis
Autoantigen Function Cleavage site Protease Fragment size Disease References
Actin Cytoskeleton LVID11, ELPD244 1 41,30,14 Autoimmune Hepatitis [95]
Alanyl tRNA synthetase Translation (VAPD632) GB 58 PM/DM, ILD [18•,51••]
CENP-B Centromere protein (VDSD457) GB 58,40 Scleroderma [18•,51••]
DNA-PK DNA repair DEVD2712 3 250,165 SLE, Scleroderma,  [37•,96]
VGPD2698 GB 250,150 Overlap Syndrome [69••]
Fibrillarin snoRNP protein VGPD184 GB 37 SLE, Scleroderma, Overlap Syndrome [51••]
a-Fodrin Actin binding protein ? Caspases 150,120 Sjögren’s Syndrome [97]
Calpain
Histidyl tRNA synthetase Translation (LGPD48) GB 40 PM, ILD, DM, Overlap Syndrome [18,51••]
Histone H3 DNA core protein RKQL20A FMDV 3Cpro 13 SLE [86]
hnRNP A1 RNA processing ? ? 32,29,16 SLE, RA, MCTD [34,98]
hnRNP C1 RNA processing ? 3,6,7 40 Scleroderma, Psoriasis [99]
hnRNP C2 RNA processing ? 3,6,7 40 Scleroderma, Psoriasis [99]
hsp-90 Stress response (DEED259) ? 54 SLE [18•,100]
Isoleucyl tRNA synthetase Translation (VTPD983) GB ? PM/DM, ILD [18•,51••]
Keratin Cytoskeleton VEVD238 3,6,7 26,22,19 GVHD, DLE [18•,100,101]
Calpain
Ki-67 Cell proliferation (VCTD1481) GB 167,148 SLE [18•,51••]
Ku-70 DNA replication, repair (ISSD79) GB ? SLE, PM/Scleroderma [18•,51••]
La Pol III transcription (DEHD371),(DEHD374) Not 1,2,3,8,9 45 SLE [54]
LEED220 GB ? [51••]
VQFQ358G PV 3Cpro 50 [84]
Lamin A Nuclear skeleton VEID230 6 45 SLE-like Disease, APLA [102,103]
Lamin B Nuclear skeleton (EEID448) ? 45,28 SLE-like Disease, APLA [40,104]
(VEVD231)
Lamin C Nuclear skeleton VEID230 6 45 SLE-like Disease, APLA [102,103]
Mi-2 DNA methylation, VDPD1312 GB 75,72,48 DM [51••]
chromatin remodeling
Nucleolin Nucleolar RNA ? ? 16 SLE [34,105]
binding protein ? GA 88 [70]h
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Table 1
Continued
Autoantigen Function Cleavage site Protease Fragment size Disease References
NuMA Mitosis ? 3,4,6,7,8 180,160 Sjögren’s Syndrome [40,106]
VATD1705 GB 175 [51••]
PARP DNA binding protein DEVD216 1,2,3,6 85,31 SLE [40,107,108] 
VDPD536 GB M (89,72,62) [69•]
PM-Scl Exoribonuclease (VEQD252) GB 85,74 PM, Scleroderma [18•,51••]
PMS1 DNA repair ISAD496 GB 50,60 ? [51••]
PMS2 DNA repair VEKD493 GB 60,50,36 ? [51••]
RNA helicase A RNA processing, transcription (DTPD96) 3 M (120-130) SLE [109]
RNA polymerase I RNA synthesis (ICPD448) GB ? Scleroderma [18•,51••]
RNA polymerase II RNA synthesis (ITPD370) GB 190,110,92 Scleroderma [18•,51••]
SP1 Transcription NSPD584 3,7 68,45,22 UCTD [110]
SRP-72 Protein translation, (SELD617) 3 66 DM/PM [33]
ER localization (VTPD573) GB 62 [51••]
Topoisomerase I DNA unwinding, DDVD146 EEED170 3 M (76-82) Scleroderma, PM [40,49]
SR protein kinase PEDD123 3
6
IEAD15 GB 98,75,72 [51••]
Topoisomerase II DNA unwinding ? ? M (125-160) SLE, Fibrosing Alveolitis [40]
Transglutaminase Protein cross-linking ? 3 48 Coeliac Disease [59,60]
UBF/NOR-90 Nucleolar transcription factor ? ? M (24,32,35,55) Sjögren’s Syndrome,  [40]
(VRPD220) GB ? Scleroderma [51••]
U1-70 kD RNA splicing DGPD341 3 40, 22 SLE, Scleroderma, MCTD [38,96]
LGND409 GB 60
Vimentin Cytoskeleton IDVD259 1,2,3,8,12 44,36,25,15 SLE, BD, RA, Sjögren’s Syndrome [104,111–113]
DSVD85
? HIV-1 protease ? [85]
The ‘Cleavage site’ column lists sites that have been definitively identified, either by mutational analysis of the substrate P1 aspartic acid residue, or by peptide sequencing of proteolytic
fragments. Sequences in parentheses signify untested but likely cleavage sites. The fourth column lists proteases that have been implicated in the cleavage reaction. Caspases are listed by
number. The substrate is susceptible to direct cleavage by the indicated recombinant caspase or by purified calpain or GB in an in vitro cleavage assay. The fifth column signifies molecular
weights (in kDa) of cleavage products as observed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The acronyms used in this table (and not included in the abbreviations list at
the start of the review) are listed in the appendix.may dysregulate their SRPK activity, leading to phosphory-
lation of serine arginine proteins [40,49]. Phosphorylated
serine arginine proteins associate with both the
U1-snRNP and the U3-snoRNP, which are major autoanti-
genic complexes in MCTD and scleroderma, respectively
([42] and our unpublished data). Although a study has not
yet been performed to address whether serine arginine
proteins are themselves targets of an immune response in
SLE, MCTD, or scleroderma, their association with the
U1-snRNP and U3-snoRNP may contribute to the
immunogenicity of other components of these important
autoantigen particles.
Several components of RNA polymerase I (ie S5 and S6)
are specifically recognized by autoantibodies derived from
SLE patients when they are phosphorylated, suggesting
that phosphorylation may play a direct role in determining
the immunogenicity of some proteins [50•]. Although their
phosphorylation state is not known to be altered in
response to stressful stimuli, RNA polymerase I compo-
nents are targets of the protease granzyme B [51••]. The
humoral arm may not be the only component of the
immune response that is influenced by the phosphoryla-
tion state of triggering antigens. T-cell recognition of phos-
phopeptides bound to self-major histocompatibility complex
Arthritis Research    Vol 2 No 2 Utz et al
Table 2
Other death-associated autoantigen modifications
Autoantigen Function Modification Disease Reference
Actin Cytoskeleton Transglutamination Autoimmune Hepatitis [58,95,114]
DNA/nucleosome Genetic code DNA cleavage SLE [18•,19,30]
DNA methylation
Fibrillarin snoRNP component Oxidative fragmentation Scleroderma [71•]
Histone H2A DNA core Ubiquitin conjugation/deconjugation SLE [19,62,63]
Histone H2B DNA core Transglutamination SLE [19,58]
La Pol III transcription Dephosphorylation SLE [54]
PARP DNA binding protein, DNA repair ADP-ribosylation SLE [57]
Necrotic fragmentation [76]
pp90 ?U2-snRNP protein Phosphorylation SLE [42]
pp34 SR splicing factor Phosphorylation SLE [41,42]
pp46 ? Phosphorylation SLE [41]
pp17 ? Phosphorylation SLE [41]
Ribosomal RNA Translational apparatus RNA cleavage SLE [31,32,115]
SRp40 SR splicing factor Phosphorylation SLE [42]
SRp55 SR splicing factor Phosphorylation SLE [42]
SRp20 SR splicing factor Phosphorylation SLE [42]
Topoisomerase I DNA unwinding, SR protein kinase Necrotic fragmentation Scleroderma [76]
Oxidative fragmentation [71•]
Topoisomerase II DNA unwinding Ubiquitin conjugation/deconjugation SLE, Fibrosing Alveolitis [40,64,116]
Troponin Muscle function Transglutamination Necrobiosis Lipoidica [58,117]
Tubulin Cytoskeleton Transglutamination SLE [58,118]
U1-70 kD mRNA splicing Necrotic fragmentation SLE, MCTD [76]
U1-snRNA mRNA splicing RNA cleavage SLE, MCTD [36]
UBF/NOR-90 Nucleolar transcription factor Oxidative fragmentation Sjögren’s Syndrome,  [71•]
Necrotic fragmentation Scleroderma [76]
Vimentin Cytoskeleton Citrullination SLE, BD, RA, [67]
Sjögren’s Syndrome
Y RNA Unknown, associates with Ro RNA cleavage SLE [35]
The acronyms used in this table (and not included in the abbreviations list at the start of the review) are listed in the appendix.(MHC) molecules has also been reported for the multiple
sclerosis autoantigen aB-crystallin [52]. T cells recog-
nized and responded to preparations of aB-crystallin that
differed in the extent of phosphorylation of aB-crystalline
at position Ser45. Interestingly, aB-crystallin is phosphory-
lated in glial cells after stressful stimuli, supporting the
concept that T cells can specifically recognize phospho-
peptides that are modified in response to stress [53].
Dephosphorylation of La and ADP-ribosylation of poly A
ribose polymerase
La is the only autoantigen identified to date that under-
goes dephosphorylation during apoptosis. In early studies,
La was shown to be partially cleaved in response to
several different apoptotic stimuli [39]. This cleavage
event has been extensively characterized by Rutjes et al
[55]. In response to a wide variety of cell death stimuli, La
is partially cleaved in vivo, probably in its carboxyl-termi-
nus, in a caspase-dependent manner. Somewhat surpris-
ingly, La is also specifically dephosphorylated at Ser366
during apoptosis [54]. The mechanism by which this
occurs is unclear and could involve inactivation of a
kinase, many of which are cleaved and dysregulated
during apoptosis [55]. Alternatively, activation of a phos-
phatase, such as protein phosphatase 2A, whose
inhibitory  a-subunit is cleaved and inactivated (resulting in
upregulated phosphatase activity) during cell death, may
also be responsible [56].
Interestingly, the enzymatic activity of poly A ribose poly-
merase (PARP) has recently been shown [57] to be tran-
siently upregulated in stressed cells before their
commitment to death, and several nuclear proteins
(including PARP itself) are ADP-ribosylated in response to
stress. This activity decreases at later time points, presum-
ably due to inactivation of PARP upon cleavage by cas-
pases. La and PARP are both excellent substrates for
granzyme B and are cleaved at sites that generate a differ-
ent pattern of proteolytic fragments than seen with
caspase-mediated cell death [51••]. Which of these modi-
fications may be involved in the generation of specific
high-titer autoantibodies in SLE and related autoimmune
diseases is an open question. This is further complicated
for La by the observation that the Y RNAs, which exist in
complex with the Ro particle, are also degraded during
apoptosis [35]. It is currently unknown whether Y RNA
cleavage is also observed in granzyme B-mediated cell
death pathways.
Transglutamination of autoantigens
‘Tissue’ transglutaminase is a widely expressed enzyme
that has several links with autoimmune disease. The
enzyme catalyzes the cross-linking of substrate proteins
through the formation of e(g-glutamyl) lysine cross-links and
N,N-bis(g-glutamyl) polyamine bonds. Several autoantigens
are specific cross-linking substrates for tissue transglutami-
nase, particularly histone H2B, a component of the nucleo-
some discussed earlier [58]. Transglutaminase messenger
RNA levels are upregulated during apoptosis [58]. The
enzymatic activity of transglutaminase is believed to be
activated early in the death process, but appears to be
crippled at a later point through a caspase 3-mediated pro-
teolytic event [59]. Proteolysis correlates with a loss of
transglutaminase cross-linking activity. Interestingly,
autoantibodies directed against transglutaminase are
highly specific markers of coeliac disease, an human leuko-
cyte antigen-DQ2-restricted inflammatory bowel disease
that is triggered by exposure of the gut to wheat gliadin
[60]. Although it is unknown whether transglutaminase
cleavage is involved in the production of antitransglutami-
nase autoantibodies, the autoantibodies to transglutami-
nase are only part of the interesting pathogenesis of this
disease. The enzymatic activity of transglutaminase has
been directly implicated in the pathogenesis of coeliac
disease. Transglutaminase mediates this effect through an
ordered series of deamidation reactions on gliadin. The
modified gliadin then binds efficiently to DQ2, which is
specifically recognized by gut-derived T lymphocytes
[61••]. The disease presumably is antibody independent, as
patients with hypogammaglobulinemia or immunoglobulin
A deficiency are not protected from development of the
disease. Thus, coeliac disease represents one of the few
examples discovered to date whereby a post-translational
autoantigen modification directly contributes to bypassing
T cell tolerance to an antigen.
Ubiquitin conjugation state of autoantigens during
apoptosis
Two autoantigens undergo alterations in their state of con-
jugation to ubiquitin. Ubiquitinated histone H2A is present
in normal cells, but is absent from cells undergoing apop-
tosis induced by transforming growth factor-b1, suggest-
ing that the ubiquitin-conjugating apparatus responsible
for maintaining ubiquitinated H2A is disrupted during
apoptosis [62,63]. The second antigen, topoisomerase
IIa, is specifically degraded through activation of the ubiq-
uitin proteolysis system in response to ectopic expression
of adenovirus E1A12S [64]. Finally, ubiquitin itself has been
identified as a scleroderma autoantigen, although it is not
known whether the antiubiquitin antibodies are initiated in
response to free ubiquitin or to ubiquitin that has been
conjugated to target substrates [65].
Citrullination of autoantigens
One of the most interesting post-translational modifications
that has been associated with autoimmune disease is the
selective deimination of arginine to form citrulline, a reaction
catalyzed by the enzyme peptidylarginine deiminase. Autoan-
tibodies that recognize citrullinated peptides have been
strongly associated with rheumatoid arthritis, with a pub-
lished specificity of 96% [66••]. The antigenic source of
these citrullinated peptides is unknown, and few proteins are
http://arthritis-research.com/content/2/2/101known to contain citrulline. These include vimentin, myelin
basic protein, and several skin-associated polypeptides such
as filaggrin, trichohyalin, keratin, and an unidentified 70-kDa
protein. Two reports suggest that peptidylarginine deiminase
may be specifically activated in response to apoptotic stres-
sors. Asaga et al [67] demonstrated that vimentin is selec-
tively deiminated when mouse peritoneal macrophages
undergo apoptosis upon exposure to calcium ionophore.
Mizoguchi et al [68] subsequently demonstrated that an
unidentified 70-kDa nuclear protein is similarly modified in
apoptotic rat keratinocytes. Moreover, ectopic expression of
peptidylarginine deiminase in these cells reproduced the
deimination of the 70-kDa protein. Identification of the rele-
vant citrullinated autoantigen that is responsible for initiating
the autoimmune response in rheumatoid arthritis would be a
crucial addition to the growing understanding of this
complex and fascinating disease.
Autoantigen cleavage by cytotoxic
T lymphocyte granule proteases
A major problem with the modifications described above
is that none of the epitopes that are produced by these
enzymes should be novel or unique. All should have been
‘seen’ before by the immune system and should not
appear foreign. Thus, if apoptosis-specific modifications
contribute to autoimmune disease, they must do so by
lowering the threshold for a pre-existing autoreactive lym-
phocyte to be activated. A much more attractive hypothe-
sis by which tolerance might be bypassed is through the
creation of truly novel epitopes that have not yet been
‘seen’ by the immune system. One recently discovered
mechanism by which this might occur is by cytotoxic
T lymphocyte (CTL)-mediated apoptosis. Natural killer
cells and CTLs kill virally infected cells and tumor cells by
releasing their granule constituents, which then activate
target cell caspase pathways through the proteolytic acti-
vation of procaspases. In addition to procaspases,
granzyme B also cleaves other host cell proteins. Casci-
ola-Rosen  et al [51••,69••] recently demonstrated that
granzyme B uniquely cleaves a wide variety of (although
not all) autoantigens (Table 1). Cleavage occurs at unique
sites not recognized by caspases activated by other apop-
totic stimuli such as irradiation or activation of death
receptors such as Fas and the tumor necrosis factor
receptor. Moreover, none of the nonautoantigenic proteins
tested (eg thrombin or vinculin) were substrates for
granzyme B in vivo or in vitro. Another CTL granule pro-
tease, granzyme A, cleaves the SLE autoantigen nucleolin
[70]. These results strongly suggest that CTL- or natural
killer cell-mediated cell death, as opposed to other forms
of apoptosis, may be extremely important in the initial
insult that generates novel peptide fragments that appear
foreign to the organism. In addition to novel epitopes gen-
erated by granzymes, several other modified antigens have
been described that are created by environmental toxins
or viruses, as discussed below.
Modifications associated with nonapoptotic
cell death
A hallmark of scleroderma is the production of autoantibod-
ies that recognize components of the nucleolus. As
expected, many of these nucleolar autoantigens are respon-
sible for ribosomal assembly, particularly in the splicing of
ribosomal RNA molecules. Unlike the situation for SLE, there
is little evidence linking apoptosis and scleroderma. Several
reports published in the past few years, however, have
offered compelling evidence that cell death, particularly by
necrosis or exposure of cells to the heavy metal mercury,
may be important events in the genesis of scleroderma.
In 1997, Casciola-Rosen et al [71•] demonstrated that
mercury, when added to cells in culture, specifically local-
ized to the nucleolus. This interesting observation sug-
gested that mercury or other toxins might somehow
damage the nucleolus, setting in motion an autoimmune
response to components of this organelle, and perhaps
leading to multisystem autoimmune disease. Because
metals are often required for oxidation reactions, these
investigators asked whether scleroderma autoantigens
might be damaged after mercury exposure. Several sclero-
derma antigens, including topoisomerase I, the large
subunit of RNA polymerase II, and UBF/NOR-90 were
indeed fragmented when exposed to mercury. Presum-
ably, similar oxidation reactions occur in the vasculature of
scleroderma patients, which is often characterized by
episodes of hypoperfusion and reperfusion.
Not all scleroderma autoantigens were observed to be
fragmented in the study of Casciola-Rosen et al [71•], sug-
gesting that other modifications might also contribute to
scleroderma pathogenesis. Pollard et al [72] had estab-
lished a murine model of the immune response to the scle-
roderma autoantigen fibrillarin. They demonstrated that
exposure of mice to mercury chloride resulted in the devel-
opment of an antinucleolar autoantibody response. Produc-
tion of these antibodies, which included antibodies that
specifically recognized fibrillarin, was genetically restricted
to the H2A region of the MHC of H-2S mice [73,74]. They
went on to demonstrate that fibrillarin is uniquely modified
by mercury chloride in such a way that it is no longer rec-
ognized by antibodies [75•]. The mercury chloride-induced
modification required the presence of two cysteine
residues, suggesting that mercury was disrupting a disul-
fide bond in fibrillarin that is required for antibody recogni-
tion. Several mechanisms have been proposed to explain
how mercury exposure breaks tolerance, including the fol-
lowing: direct activation of autoreactive T cells by binding
of metal to MHC and/or peptide; and stable interaction of
metal with self proteins, which then undergo selective or
novel proteolysis by APCs (for review [75•]).
Exposure of cells to other environmental toxins or stressors
such as ethanol, mercury chloride, hydrogen peroxide, or
Arthritis Research    Vol 2 No 2 Utz et alheat shock results in a distinct form of nonapoptotic cell
death that is caspase-independent. Autoantigens are also
uniquely modified in response to these diverse cellular
stressors. For example, antigens such as PARP, topoiso-
merase I, UBF/NOR-90, and U1-70 kD are fragmented
after necrotic stimuli, and the fragments are distinct from
the caspase-derived fragments observed during apoptosis
[76]. Together with the studies involving mercury expo-
sure, these reports provide in vitro and in vivo evidence
that an environmental toxin may contribute to the develop-
ment of a specific autoimmune response.
Modifications associated with viral infection
A number of clinical observations suggests that infection
of genetically susceptible individuals with as yet unidenti-
fied virus(es) may trigger or exacerbate autoimmune dis-
eases such as SLE. This might result from the host
response to the virally-infected cell (eg CTL-mediated
killing discussed above), or from disruption of normal cel-
lular functions by virally-encoded factors. Several other
mechanisms by which viral infection may be involved in the
pathogenesis of autoimmune disease have also been
described, albeit in a different context. First, many host
proteins specifically interact with viral nucleic acid. The La
protein, for example, binds to hepatitis C virus, human
immunodeficiency virus, and Epstein–Barr virus RNA
[77–79]. The forgotten interaction of La with Epstein–Barr
virus RNAs EBER 1 and EBER 2 will almost certainly be
revisited [80]. Epstein–Barr virus infection has been
strongly correlated with the development of SLE in a
recent report [81••]. Second, several viral proteins have
been identified that interact directly and specifically with
host proteins. The most intriguing examples are the herpes
simplex virus proteins open reading frame (ORF)-P, unique
region protein 6 (UL6), and infected cell protein (ICP)27.
All three viral RNA binding proteins have been shown to
interact with components of the host spliceosome, either
by coprecipitation analysis (UL6 and ICP27) or in the
yeast two-hybrid system (ORF-P) [82,83] (unpublished
data). Both mechanisms (ie stable association of viral
nucleic acid or protein with host proteins) have the poten-
tial to break tolerance to the host antigen. This could
occur if the initial immune response to the viral antigen
spreads to the host protein(s) in the complex by ‘epitope
spreading’. Alternatively, binding of the viral RNA or
protein to host autoantigens might change either the con-
formation of the antigen or the processing of the host
antigen by APCs.
The genomes of several viruses, particularly picor-
naviruses (eg poliovirus) and flaviviruses (eg West Nile
virus) encode proteins with the potential to modify host
proteins directly. For example, the poliovirus genome
encodes proteases that are required for processing of viral
polypeptides. Host proteins are also substrates for these
proteases, and their proteolytic degradation serves an
important function in the viral lifecycle by insuring that host
protein synthesis is shut off while cap-independent (inter-
nally-initiated) viral protein synthesis is preferentially acti-
vated. It has recently been demonstrated that the La
autoantigen is an important host substrate for poliovirus
3C protease. La is cleaved between Gln358 and Gly359,
removing a carboxyl-terminal nuclear localization motif.
This prevents La from shuttling from the cytoplasm back to
the nucleus [84]. Interestingly, the poliovirus 3C protease
cleavage site lies in close proximity to the putative
caspase cleavage site identified by Rutjes et al [54].
Cleavage by a viral protease at such a novel site has the
potential to create neoepitopes required to break toler-
ance to this molecule. Other examples of autoantigens
that are substrates for viral proteases include vimentin (a
substrate for human immunodeficiency virus-1 protease)
and histone H3 (a substrate for foot-and-mouth disease
virus protease 3C) [84–86]. Substrate-specific autoanti-
bodies have not been reported to occur in association
with any of these viral infections, although it is not clear
such associations have been sought.
Conclusion
Since the ‘rediscovery’ 6 years ago by Casciola-Rosen et
al that apoptotic stimuli may be critically important in
breaking tolerance to important autoantigens, an increas-
ing number of death-associated autoantigen modifications
have been identified [12••,38]. Although proteins that are
modified during apoptosis are preferred targets of the
autoantibodies found in the serum of patients with autoim-
mune disease, it is clear that apoptosis per se is not suffi-
cient to break tolerance to these self proteins. In the adult
human, millions of cells undergo apoptosis each and every
hour, but most people do not develop autoimmune
disease. The normal process of apoptosis, refined over
evolutionary millennia, is extremely efficient and extraordi-
narily rapid. In most tissues, the apoptotic cell undergoes
nuclear and cytoplasmic condensation, nuclear fragmenta-
tion, and clearance by neighboring parenchymal cells in
less than 1h. Because of this, the apoptotic index (ie the
percentage of cells in a tissue that exhibit an apoptotic
morphology) tends to be low (usually less than 1%), even
in tissues such as the thymus gland in which negative and
positive selection result in the apoptotic elimination of
more than 90% of immigrant thymocytes. Consistent with
this notion, immunization of BALB/c mice with apoptotic
syngeneic cells does not result in the production of patho-
genic autoantibodies that are reactive with Smith complex,
Ro and La, nor is it associated with the onset of a lupus-
like autoimmune disease [87•].
The problem occurs when the execution, or clearance of
the apoptotic cell is delayed. This phenomenon has been
demonstrated in mice lacking the first component of com-
plement. C1q functions as an opsonin that binds to apop-
totic cells and promotes their clearance by professional
http://arthritis-research.com/content/2/2/101APCs. In the absence of C1, the clearance of apoptotic
corpses is delayed, and the apoptotic index increases in
tissues such as the kidney [88]. Delayed clearance of
apoptotic cells somehow increases their immunogenicity.
A similar phenomenon occurs when the execution of the
apoptotic program is delayed. Thus, influenza virus-
induced apoptosis in macrophages has been shown to
increase the immunogenicity of viral proteins [89,90]. This
phenomenon requires the phagocytosis of the infected
macrophage by dendritic cells. By a process of cross-
priming, the dendritic cell can then present antigens
derived from the infected macrophage in a highly efficient
manner. Because influenza virus encodes several genes
that function to inhibit apoptosis (eg NS1), virus-induced
apoptosis requires many hours to complete. This delay
allows the virus to replicate within the infected cell.
Because virus infection is a potent inducer of the cellular
stress response, this delay also allows infected cells to
induce the expression of stress response proteins such as
heat shock proteins 70 and 90. These proteins are
peptide-binding proteins that can function as natural adju-
vants to promote the immune response to peptide anti-
gens [91]. These proteins also function as chaperones
that normally deliver peptides generated at the protea-
some to the transporter in antigen processing at the endo-
plasmic reticulum membrane, and so are important in
loading peptides onto MHC molecules. It is therefore pos-
sible that the heat shock proteins function to deliver
altered self-peptides formed in apoptotic cells to the MHC
complex of APCs by a mechanism of cross-priming. By
this mechanism, delays in the execution of apoptosis, or
the clearance of apoptotic cells, could promote autoimmu-
nity to proteins modified during apoptosis. It will therefore
be important to determine whether defects in the execu-
tion and/or clearance of apoptotic cells occurs in patients
with autoimmune disease.
Another important unexplained question is how proteins
expressed in every cell become targets of organ-specific
autoimmune diseases. The simplest (and perhaps overly
naïve) explanation for organ specificity would be if a partic-
ular apoptotic trigger (eg expression of Fas/Fas ligand, or
viral infection) was inappropriately switched ‘on’ in the
target organ. Such a mechanism might in part explain dis-
eases such as polymyositis or type I (insulin-dependent)
diabetes mellitus, both of which are characterized by
impressive inflammation of the target organ and produc-
tion of specific subsets of autoantibodies. Interestingly,
several polymyositis-specific autoantigens (eg transfer
RNA synthetases and Mi-2) are substrates for granzyme B
[51••]. This raises the intriguing possibility that a muscle-
trophic virus infects susceptible individuals, and that the
CTL response to virally-infected cells generates neoepi-
topes of transfer RNA synthetases and Mi-2 to which
autoantibodies are eventually produced. This concept is
supported by several observations made over a decade
ago, including the identification of CTLs in polymyositis
biopsy specimens, and the serologic association of spe-
cific viral infections with myositis [92,93]. Similar mecha-
nisms might underlie diseases such as multiple sclerosis
and rheumatoid arthritis. Until the precise autoantigens
responsible for initiating these latter diseases are identi-
fied and characterized, however, any attempts to explain
the organ-specific nature of the autoantibodies would be
purely speculative.
Finally, why is the autoantibody profile in patients with
autoimmune diseases (particularly SLE) pleiotropic? This
question has fascinated clinicians for decades. Several
lines of evidence suggest that the immune response to
autoantigens is driven by repeated exposure of the individ-
ual to intact ‘particles’ (eg spliceosomes, nucleosomes, or
ribosomes; for review [94•]). Which of these particles is
chosen as an immunogen may depend on the genetic
background of the individual, the nature of the death stim-
ulus, the susceptibility of individual cells to the stimulus,
the packaging of autoantigen combinations within cell
surface blebs, and the clearance and processing of parti-
cles by APCs described earlier. The striking take-home
message of the present review is that at least one death-
associated autoantigen modification, and often several
modifications, affect at least one component of every
major disease-specific autoantigen particle that has been
identified to date (Tables 1 and 2).
It is an exciting time for all investigators who endeavor to
understand better the mechanisms involved in breaking
tolerance to self-antigens. If the questions posed above
can be successfully answered, then the etiology of many
common diseases such as rheumatoid arthritis, SLE, and
type I (insulin-dependent) diabetes mellitus may be eluci-
dated, if not solved. With this solution may come more
promising disease-specific, antigen-specific, or even
patient-specific therapies in the new millennium, hopefully
to replace the inadequate modalities used in 20th century
clinical practice.
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Appendix
Acronyms used in the tables and not listed in the abbrevia-
tions list on the first page of this review are given below:
APLA = antiphospholipid antibody syndrome;
BD = Behçet’s disease;
CENP = centromere protein;
CREST = syndrome of calcinosis, Raynaud’s
phenomenon, esophageal dysmotility, sclerodactyly, and
telangectasias;
DLE = discoid lupus erythematosus;
DM = dermatomyositis;
DNA-PK = DNA-dependent protein kinase;
ER = endoplasmic reticulum;
GA = granzyme A;
GB = granzyme B;
GVHD =  graft-versus-host disease;
HIV-1 = human immunodeficiency virus 1;
hnRNP = heterogeneous ribonuclear protein;
hsp = heat shock protein;
ILD = interstitial lung disease;
MCTD = mixed connective tissue disease;
NuMA = nuclear mitotic-associated protein;
PM = polymyositis;
PM-Scl = polymyositis-scleroderma autoantigen;
Pol III = RNA polymerase III;
RA = rheumatoid arthritis;
SLE = systemic lupus erythematosus;
snoRNP = small nucleolar ribonuclear protein;
SP1 = transcription factor;
SR = serine/arginine-rich splicing factors;
SRPK = SR protein kinase;
SRP 72 = the 72-kDa component of signal recognition
particle;
tRNA = transfer RNA;
U1-70 kD = the 70-kDa component of the U1-snRNP;
UBF/NOR-90 = nucleolar organizing region;
UCTD = undifferentiated connective tissue disease.
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